Skip to content
by Legal Desire
20 July 2022

Latham & Watkins advises Revolution Medicines in its US$230 Public OfferingMillion

Advising firms

Deal team

16 lawyers named
LawyerFirmSeniorityPracticeOffice
Mark Roeder Lead Latham & Watkins LLP Partner corporate Bay Area
John Williams Lead Latham & Watkins LLP Partner corporate Bay Area
Zuzanna Gruca Latham & Watkins LLP Associate corporate Not stated
Taimi Jacobson Latham & Watkins LLP Associate corporate Not stated
Joshua Landis Latham & Watkins LLP Associate corporate Not stated
John Manthei Latham & Watkins LLP Partner regulatory Washington, D.C.
Elizabeth Richards Latham & Watkins LLP Partner regulatory Washington, D.C.
Heather Deixler Latham & Watkins LLP Partner regulatory Bay Area
Betty Pang Latham & Watkins LLP Counsel regulatory Bay Area
Nathan Beaton Latham & Watkins LLP Associate regulatory Washington, D.C.
Leia Gu Latham & Watkins LLP Associate regulatory Los Angeles
Grace Lee Latham & Watkins LLP Partner tax Bay Area
Derek Gumm Latham & Watkins LLP Associate tax Not stated
James Metz Latham & Watkins LLP Partner benefits and compensation Bay Area
Christopher Hazuka Latham & Watkins LLP Partner intellectual property Bay Area
Kristina Funahashi Latham & Watkins LLP Associate intellectual property San Diego

Stated terms

Stated value
USD 230m (US$230 million)
What the figure measures
Issue size
Client
Revolution Medicines, Inc.Issuer
Counterparties
Not stated